Cargando…

Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors

Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrin...

Descripción completa

Detalles Bibliográficos
Autores principales: Coughlan, Lynda, Alba, Raul, Parker, Alan L., Bradshaw, Angela C., McNeish, Iain A., Nicklin, Stuart A., Baker, Andrew H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185574/
https://www.ncbi.nlm.nih.gov/pubmed/21994621
http://dx.doi.org/10.3390/v2102290
_version_ 1782213235698565120
author Coughlan, Lynda
Alba, Raul
Parker, Alan L.
Bradshaw, Angela C.
McNeish, Iain A.
Nicklin, Stuart A.
Baker, Andrew H.
author_facet Coughlan, Lynda
Alba, Raul
Parker, Alan L.
Bradshaw, Angela C.
McNeish, Iain A.
Nicklin, Stuart A.
Baker, Andrew H.
author_sort Coughlan, Lynda
collection PubMed
description Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” interactions. “Bridging” interactions refer to coagulation factor binding, namely coagulation factor X (FX), which bridges hepatocyte transduction in vivo through engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These interactions can contribute to the off-target sequestration of Ad5 in the liver and its characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various approaches to retargeting adenoviruses (Ad) have been described. These include genetic modification strategies to incorporate peptide ligands (within fiber knob domain, fiber shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with capsid proteins derived from other viral families, hexon hypervariable region (HVR) substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or monoclonal antibodies directed against surface-expressed target antigens. In order to maximize retargeting, strategies which permit detargeting from undesirable interactions between the Ad capsid and components of the circulatory system (e.g. coagulation factors, erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. Detargeting can be achieved by genetic ablation of native receptor-binding determinants, ablation of “bridging interactions” such as those which occur between the hexon of Ad5 and coagulation factor X (FX), or alternatively, through the use of polymer-coated “stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting can be achieved by combining multiple genetic and/or chemical modifications.
format Online
Article
Text
id pubmed-3185574
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-31855742011-10-12 Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors Coughlan, Lynda Alba, Raul Parker, Alan L. Bradshaw, Angela C. McNeish, Iain A. Nicklin, Stuart A. Baker, Andrew H. Viruses Review Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors must combine efficient retargeting strategies with detargeting modifications to ablate native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” interactions. “Bridging” interactions refer to coagulation factor binding, namely coagulation factor X (FX), which bridges hepatocyte transduction in vivo through engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These interactions can contribute to the off-target sequestration of Ad5 in the liver and its characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various approaches to retargeting adenoviruses (Ad) have been described. These include genetic modification strategies to incorporate peptide ligands (within fiber knob domain, fiber shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with capsid proteins derived from other viral families, hexon hypervariable region (HVR) substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or monoclonal antibodies directed against surface-expressed target antigens. In order to maximize retargeting, strategies which permit detargeting from undesirable interactions between the Ad capsid and components of the circulatory system (e.g. coagulation factors, erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. Detargeting can be achieved by genetic ablation of native receptor-binding determinants, ablation of “bridging interactions” such as those which occur between the hexon of Ad5 and coagulation factor X (FX), or alternatively, through the use of polymer-coated “stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting can be achieved by combining multiple genetic and/or chemical modifications. Molecular Diversity Preservation International (MDPI) 2010-10-13 /pmc/articles/PMC3185574/ /pubmed/21994621 http://dx.doi.org/10.3390/v2102290 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0 This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Coughlan, Lynda
Alba, Raul
Parker, Alan L.
Bradshaw, Angela C.
McNeish, Iain A.
Nicklin, Stuart A.
Baker, Andrew H.
Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
title Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
title_full Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
title_fullStr Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
title_full_unstemmed Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
title_short Tropism-Modification Strategies for Targeted Gene Delivery Using Adenoviral Vectors
title_sort tropism-modification strategies for targeted gene delivery using adenoviral vectors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3185574/
https://www.ncbi.nlm.nih.gov/pubmed/21994621
http://dx.doi.org/10.3390/v2102290
work_keys_str_mv AT coughlanlynda tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors
AT albaraul tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors
AT parkeralanl tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors
AT bradshawangelac tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors
AT mcneishiaina tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors
AT nicklinstuarta tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors
AT bakerandrewh tropismmodificationstrategiesfortargetedgenedeliveryusingadenoviralvectors